did you even listen to the cc? 80M this year, 80M next year. Only 2 programs, no details on partnering, no great or even good answers to questions from the CEO. Lot's has changed. Still incredible technology, but I doubt mgmt will extract all the value.
These priced drops are beyond what IR could influence. Some other factors are influencing the price at the moment. First off shorts were taken for a ride and the stock shut up too far for the moment. I suspect shorts who want out are already out. Remaining shorts may not buy in coming weeks. Second, hot money moved in and enjoyed the ride too. Those guys will be out for now. Third, Fid. Growth Company reduced holdings (from 3M to 2.8M in december) (200k shares about $8!! was it for tax purposes? did they buy it back in Jan?) Fourth, some new funds are building position. Perhaps they stepped in on Friday to push from 11.70 to 12.15 by the end of the day. Fifth, perhaps index and biotech funds are deploying incoming funds Sixth, biotech ETFs are buying. Biotech has been on fire since late last year. Pay attention to steady accumulation at the last 15 minutes before closing. ETFs rebalance their books at the end of the day.
I sold last batch on Thursday at $13.05. I am hoping to rebuild in low 11 or below, if we get lucky. I won't rush in for now. Early march may be a better time. I have nothing to ask IR for but their PR person to ask for more of the same steady positive news.